Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

 at the Grand Wailea Hotel, a session titled ‘Contact Dermatitis Update 2026’ highlighted the evolving challenges of diagnosing and managing contact dermatitis.

 Presented by Walter Liszewski, MD, associate professor of dermatology and cancer epidemiology at Northwestern University’s Feinberg School of Medicine, this session emphasized several key points, including noting the limitations of existing patch-testing Core Series panels.

’s editorial team, Liszewski spoke about these key takeaways from the session, addressing common diagnostic pitfalls and stressing the importance of distinguishing allergic contact dermatitis from atopic dermatitis, given that targeted biologic therapies for atopic disease may not improve allergic etiologies. These points and others are highlighted in this Q&A transcript of his interview:

Dr. Liszewski, thanks so much for taking the time to speak with us today. Firstly, what are the most important changes or updates from the past year that you feel are important for clinicians to recognize?

 It's a couple of different things. First is that in patch testing, we have different ‘Core Series.’ These are allergens that we set nationally for the US and Canada that will catch the most common allergens. But they're not updated annually. What we start to see is that, in between the periodic updates, which occur every three to five years, there may be new allergens that are all of a sudden becoming very relevant. A couple of these that I emphasize, the big one is benzisothiazolinone.

It is not in the American contact dermatitis series, nor is it in the T.R.U.E. TEST. It's structurally similar to methylisothiazolinone and methylchloroisothiazolinone. Benzisothiazolinone is used predominantly in hand soaps, dish soaps, and laundry detergents. But it's less problematic. So many dermatologists may not have heard of benzisothiazolinone, let alone know how to counsel their patients about it. So, if you have a patient with recalcitrant hand dermatitis or weird rashes on their hands and arms, be sure to look at their hand soap, look at their dish soap, and make sure it does not contain benzisothiazolinone.

We know you discussed a range of dermatitis dilemmas. What were some of the most challenging or commonly mismanaged scenarios that you highlight?

There are two major ones. The first is chronic hand eczema. Chronic hand eczema is not atopic dermatitis. It can be in some circumstances, but for many patients with chronic hand eczema, they have a multifactorial cause of their dermatitis. There's allergic contact dermatitis, there's irritant contact dermatitis, and there can also be atopic dermatitis, but more often than not, it's multifactorial. The pearls I give [include one suggesting] that if you have a patient with chronic hand eczema, start with a prescription topical, but if that's still not working, then you should consider doing patch testing to make sure that there's not an allergenic cause.

The second thing I talk about is chronic lip dermatitis or colitis; more often than not, it's not an allergy. You can do patch testing, but you're probably not going to find anything. Most cases of chronic lip dermatitis are due to irritants. They're due to chronic lip licking. They're due to using too many skin care products. What patients in this group really benefit from is establishing a new treatment regimen. Simplify their products down, switch to thick barrier creams like Vaseline or Aquaphor, and try to pivot to using more hypoallergenic toothpaste in skincare products.

 Were there any allergens, exposures, or patient behaviors that you emphasized as increasingly relevant in 2026?

I think the big thing is [regarding] gel nails and acrylic nails, but predominantly gel nails. Gel nails have been very popular in the past couple of years, but there have been numerous new at-home kits. They're excellent, so consumers are doing them more at home. The issue is that, historically, the major allergen in gel nails was something called 2-Hydroxyethyl methacrylate or HEMA. It's part of a larger group of adhesives called methacrylates. The issue is that the industry is now starting to use all kinds of different methacrylates. If you have a patient who comes in with allergies, and you suspect that there's an allergy to their acrylic or gel nails, if you're only testing with a standard series, which would be the ACDS Core Allergen Series or the North American Core, you're only going to be testing for Hydroxyethyl methacrylate.

The T.R.U.E. TEST does not even test for Hydroxyethyl methacrylate. So, if you have a patient like this, and you have a very high suspicion for a gel nail allergy, and they didn't react to HEMA, there's a good chance they were reacting to a different methacrylate. As someone who does extended patch testing, I have an additional 20 methacrylates I can test. I routinely test on an extended tray to make sure I'm not missing any methacrylate allergies. But if you're someone who doesn't have that available, it's just important to remember that HEMA, although it catches many forms of gel nail allergies, given that there's so much heterogeneity currently in the market for the glues that companies are using, it may not catch all cases.

How did you recommend clinicians refine their diagnostic approach when contact dermatitis overlaps with atopic or other inflammatory diseases?

It's difficult. The challenging thing is that for atopic dermatitis, there is no diagnostic test, but for allergic contact dermatitis. So if you have a patient with moderate to severe eczema and it's not improving with topicals, those patients are candidates for patch testing. If you find an allergy and they get better, you know that there was either an exclusive allergic reaction or part of the dermatitis was due to allergies. However, if you do patch testing and there are no allergens, then you know that their allergen is either irritant dermatitis or exclusively atopic dermatitis in nature. The reason why that's important is that many of the drugs we use to treat atopic dermatitis, like lebrikizumab or dupilumab, will not be effective for most forms of allergic contact dermatitis. So identifying a precise cause is very important, because not all treatments will work for all forms of eczema.

If clinicians could take away only one or two practice-changing points from your session, what would you want them to remember?

The first thing is, we always need more people to do patch testing. And I'm someone who specializes in advanced patch testing. I have 500 allergens in my clinic. I routinely test patients for more than 100 allergens. Technically, yes, that is the ideal way it should be done. But that's not the only way that needs to be done. And if you're someone who can only do the American contact dermatitis 90 allergens, or even just the T.R.U.E. TEST, it can still be helpful. We need more dermatologists who are willing and capable of doing patch testing, because it can be transformative for many of our patients with chronic eczematous dermatitis.

The second thing that I would emphasize is that you need to read labels. One thing that I encourage all of you to do is next time you're at the grocery store, you're at a pharmacy, and you're looking at shampoos or lotions, look at a bunch of them. Look at the ingredients. Are there new chemicals you haven't seen before? Are there certain chemicals that you used to see all the time, like methylisothiazolinone, that just aren't there anymore, or methyldibromo glutaronitrile? Some chemicals become popular, and then they go away. I think it's very important for us to know what are the chemicals that our patients are coming in contact with, so that we can better identify potential causes and tailor our patch testing to their needs.

The quotes used in this summary were edited for the purposes of clarity.

Liszewski did not have any relevant disclosures of note.

Liszewski W. Contact Dermatitis Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Schalock PC, Dunnick CA, American Contact Dermatitis Society Core Allergen Series Committee, et al. American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis. 2020 Sep-Oct;31(5):279-282. doi: 10.1097/DER.0000000000000621. PMID: 32947457.

Articles

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Summarizing Key Updates in Contact Dermatitis Management 2026, With Walter Liszewski, MD

Sustained HAE Attack Reductions at 18 Months with Berotralstat, With Raffi Tachdjian, MD

In a large real-world cohort, berotralstat initiation was associated with significant reductions in monthly 

 attack rates at 12 months, with sustained benefit through 18 months across HAE subtypes and baseline severities.

“The exciting thing about this study is that it basically represents one of the largest real-world patient population cohorts that are receiving long-term prophylaxis for hereditary angioedema, and this included patients with normal C1 inhibitor HAE,” Raffi Tachdjian, MD, MPH, from the department of pediatrics at the University of California Los Angeles, told 

 “This is a population in which the clinical data are limited.”

The retrospective analysis leveraged specialty pharmacy data from Optime Care, between December 2020 and January 2024. Investigators evaluated 390 patients with HAE with C1 esterase inhibitor (C1INH) and 311 with normal C1INH (HAE-nC1INH) who had at ≥ 2 dispensing and documented attack assessments before and after treatment initiation. Patients were stratified by baseline attack frequency (≥ 5, 2–4, 1, or 0 attacks per month).

Over 12 months, mean monthly attack rates fell from 2.50 to 0.79 among patients with HAE-C1INH and from 4.59 to 1.68 among those with HAE-nC1INH (both 

 < .001), with reductions maintained through 18 months of follow-up. Reductions were observed regardless of baseline attack frequency or HAE subtype.

Among patients with ≥1 attack per month at baseline, initiation of berotralstat resulted in statistically significant declines in attack rates. Most patients with 0 baseline attacks per month-maintained attack-free status during follow-up (70–85% in HAE-C1INH; 61–81% in HAE-nC1INH), reinforcing the durability of response.

Tachdjian underscored the importance of re-discussing prophylactic options with clinicians. He characterized berotralstat as a viable first-line option or alternative for patients dissatisfied with injectable prophylaxis, particularly those with needle aversion or treatment fatigue. With recent label expansion down to age 2 years, he said that the oral agent now spans a broader pediatric-to-adult population.

“I don't think there remain too many unanswered questions as far as durability or tolerability,”

“Obviously, we continue to have vigilance in any drug that's out there, but whether it's the specialty pharmacy data, obviously, the clinical trials, the pivotal phase 3 data that is read out, really point to the fact that this has efficacy and safety, both things we look for. In my mind…there's compliance with the regimen and reporting back on any kind of attacks or safety signals to make sure that they are being taken care of in this prophylactic environment.”

Videos

Real world study shows significant 12- and 18-month attack rate reductions across HAE subtypes and baseline severities following berotralstat initiation.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

The Dangers of Compounded Oral GLP-1s

On February 9, 2026, Novo Nordisk announced that it had filed a lawsuit against Hims & Hers, alleging patent infringement over Hims’ compounded semaglutide products. The document goes on to suggest that these drugs are technically unapproved and therefore may be unsafe for consumers, particularly given that oral Wegovy is the only GLP-1 pill to receive approval from the 

Diabetes Dialogue hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down to discuss the controversy and the larger issue of compounded GLP-1 formulations.

Check out the full episode on oral GLP-1s 

In this segment, the discussion focuses on the growing controversy surrounding compounded oral semaglutide products in the wake of resolved GLP-1 receptor agonist shortages. The speakers emphasize that prior supply constraints affecting both injectable and oral semaglutide formulations have largely been eliminated, with consistent access across doses now reported in routine clinical practice. Despite restored availability, new market entrants—including Hims & Hers—have introduced lower-cost oral semaglutide offerings, prompting swift legal action from Novo Nordisk.

Central to the dispute is the proprietary absorption enhancer (SNAC) required for effective oral semaglutide bioavailability. Oral delivery of GLP-1 receptor agonists presents substantial pharmacokinetic challenges, and the commercial formulation of Wegovy and related oral semaglutide products relies on highly specific absorption technology developed and patented by Novo Nordisk. The speakers underscore that this enhancer cannot be readily replicated without intellectual property and regulatory implications. As such, questions arise regarding what excipients or delivery mechanisms compounded versions are employing—and whether these have undergone any formal pharmacologic validation.

The conversation highlights the broader regulatory and safety concerns associated with compounded oral formulations. Unlike FDA-approved medications, which require extensive phase 1–4 clinical trial evaluation, compounded alternatives may enter the market without rigorous assessment of pharmacodynamics, pharmacokinetics, dose proportionality, or long-term safety. Given the inherent difficulty of achieving adequate gastrointestinal absorption of peptide-based therapies, the speakers raise the possibility that some compounded oral semaglutide products may offer minimal systemic exposure, effectively functioning as placebos. At worst, the use of untested absorption enhancers or excipients could introduce unanticipated toxicity.

At the same time, the speakers acknowledge strong patient demand for lower-cost GLP-1 therapies. They note substantial progress in price reductions compared with earlier list prices exceeding $1,000 per month, with current branded options beginning at considerably lower entry points. Nevertheless, they stress that cost-containment strategies must remain aligned with regulatory oversight and evidence-based standards.

The segment concludes with a cautionary message to clinicians and patients: while expanding access to obesity and metabolic therapies is critical, compounded oral GLP-1 formulations warrant skepticism in the absence of transparent safety and efficacy data. With commercial supply stabilized, the speakers advocate prioritizing FDA-approved therapies to ensure both therapeutic integrity and patient safety.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Novo Nordisk. Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers. February 5, 2026. Accessed February 16, 2026. 

https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916489

Novo Nordisk. Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic. February 9, 2026. Accessed February 16, 2026. 

https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916493

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

MAJESTY, the first global phase 3 study in 

, met its primary endpoint of complete remission at 2 years with obinutuzumab (Gazyva).

Genentech announced the positive 2-year phase 3 results of obinutuzumab compared to tacrolimus on February 16, 2026, with the potential for the therapeutic to become the first approved treatment for PMN.

“These results demonstrate that obinutuzumab may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer, and delay or potentially prevent the onset of life-threatening complications,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, in a statement. “If approved, Gazyva would be the first therapy specifically indicated for people with primary membranous nephropathy, where there are limited treatment options.”

In patients with PMN, approximately 30 to 40% with severe proteinuria progress to end-stage renal disease or experience significant, irreversible kidney failure 10 years postdiagnosis. A major driver of adverse clinical outcomes is failure to achieve remission, which has been associated with increased rates of needing replacement renal therapy and death.

Obinutuzumab is a humanized monoclonal antibody designed with a type II anti-CD20 region for direct B-cell death and a glycoengineered Fc region for increased binding affinity and increased antibody-dependent cellular cytotoxicity. The therapy has already been approved for adults with 

 and in 100 countries for various types of hematological cancers.

MAJESTY, the phase 3 randomized, open-label, multicenter study, evaluated the efficacy and safety of obinutuzumab compared to tacrolimus in patients with PMN. The study included 142 participants who were randomized in a 1:1 ratio to receive either obinutuzumab or tacrolimus. The primary endpoint was the percentage of people who achieved complete remission at week 104, or 2 years.

From the primary results, investigators reported statistically significant and clinically meaningful results with obinutuzumab in achieving complete remission at 2 years. Overall, safety was in line with the previous safety profile of obinutuzumab, with no new safety signals identified.

Upon analysis of key secondary endpoints, investigators observed statistically significant and clinically meaningful benefits in patients treated with obinutuzumab compared to those treated with tacrolimus in overall remission, complete or partial, at week 104 and complete remission at week 76.

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease. BusinessWire. Published February 16, 2026. Accessed February 16, 2026. 

https://www.businesswire.com/news/home/20260215765811/en/Genentech-Announces-Positive-Phase-III-Results-for-Gazyva-in-Primary-Membranous-Nephropathy-Marking-a-Significant-Milestone-in-This-Autoimmune-Disease

Westermann L, Rottmann FA, Hug MJ, et al. Clinical covariates influencing clinical outcomes in primary membranous nephropathy. 

https://doi.org/10.1186/s12882-023-03288-x

MAJESTY, a phase 3 study evaluating obinutuzumab in primary membranous nephropathy, demonstrates positive efficacy and safety.  


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

In this episode, “The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data” the expert hepatologists explore key safety data from the ELATIVE trial on elafibranor and from RESPONSE on seladelpar.

Led by the moderator, the panelists examine the following critical question:

What have we learned about the safety of PPAR agonists from the primary trials of elafibranor (ELATIVE) and seladelpar (RESPONSE)?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, “Addressing Fatigue: Traditional Management Outside Primary Therapy,” features the panelists advancing their conversation on PBC and focusing on how they typically manage patient fatigue beyond primary therapies. They discuss how to coach patients into beneficial health and wellness routines to reduce fatigue, and stress the importance of a regular sleeping schedule.

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

Abraham Kazemi, MD, is the director of Cosmetic and Laser Dermatology for Virginia’s Pinnacle Dermatology sites.

This Skin of Color Savvy episode featured Abrahem Kazemi, MD, who speaks on several notable experiences he had as a dermatologist.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Serving the Underserved in Dermatology, With Abrahem Kazemi, MD

Explore the latest FDA-approved second-line therapies for PBC, including seladelpar and elafibranor, and their mechanisms of action.

The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

A new study found no association between antibiotic class or number of classes in infancy and later allergic disease, reinforcing stewardship over substitution.


No Class-Specific Early-Life Antibiotics Linked to Allergy, With Moath Hattab, MD

Stay updated with the latest healthcare breakthroughs, FDA actions and new phase 2 and 3 data, in this week’s essential news roundup.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 02/08

Ruchika Goel, MD, is a professor and associate vice chair of research at SIU School of Medicine.

In pediatric platelet transfusions, what counts as success depends on the clinical context and treatment goals, not just the platelet count.

Hematology

Rethinking What Defines Success in Pediatric Platelet Transfusion, With Ruchika Goel, MD

Dawn Eichenfield, MD, PhD, is a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at UC San Diego School of Medicine.

Eichenfield speaks in this interview about several key takeaways drawn from her master class in pediatric dermatology at Maui Derm Hawaii.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

New Pediatric Atopic Dermatitis Updates for 2026, With Dawn Eichenfield, MD, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Experts discuss shifting CKD detection upstream, improving albuminuria screening, and enabling earlier, risk-based intervention.

Chronic Kidney Disease

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Rethinking Early Detection of CKD: A Shift Toward Upstream Care

The FDA denied accelerated approval for bitopertin, citing a need for evidence on clinical benefit from the ongoing phase 3 APOLLO trial. 


RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

FDA News

FDA Issues Complete Response Letter to Bitopertin For Erythropoietic Protoporphyria

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Ozempic’s approval in a higher-dose oral form and lingering concerns over compounded drugs.

Strategic Alliance Partnership

Diabetes Dialogue: Oral Ozempic and the Risks of Compounding Formulas

Sophie Stocker, BsC, PhD, is a senior hospital scientist at St Vincent’s Hospital Sydney, and a senior lecturer at The University of Sydney

Stocker discusses findings from a pilot phase trial with clinical insight into a wearable patch for continuous drug measurement of vancomycin. 


Latest News

Summarizing Key Updates in Contact Dermatitis Management 2026, With Walter Liszewski, MD

Sustained HAE Attack Reductions at 18 Months with Berotralstat, With Raffi Tachdjian, MD

The Dangers of Compounded Oral GLP-1s

MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data